EGFR mutations in non‑small cell lung cancer: Classification, characteristics and resistance to third‑generation EGFR‑tyrosine kinase inhibitors (Review)
- Authors:
- Zhe Tian
- Lilan Cen
- Feng Wei
- Jue Dong
- Yulan Huang
- Yi Han
- Zhibo Wang
- Junhua Deng
- Yujie Jiang
-
Affiliations: Department of Pulmonary and Critical Care Medicine, Life Science and Clinical Medicine Research Center, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi Zhuang Autonomous Region 533000, P.R. China, Department of Infectious Disease, Guangxi Academy of Medical Sciences, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China - Published online on: June 2, 2025 https://doi.org/10.3892/ol.2025.15121
- Article Number: 375
-
Copyright: © Tian et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Suster DI and Mino-Kenudson M: Molecular pathology of primary non-small cell lung cancer. Arch Med Res. 51:784–798. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Chen P, Liu Y, Wen Y and Zhou C: Non-small cell lung cancer in China. Cancer Commun (Lond). 42:937–970. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Houghton AM: Common mechanisms linking chronic obstructive pulmonary disease and lung cancer. Ann Am Thorac Soc. 15 (Suppl 4):S273–S277. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Duréndez-Sáez E, Torres-Martinez S, Calabuig-Fariñas S, Meri-Abad M, Ferrero-Gimeno M and Camps C: Exosomal microRNAs in non-small cell lung cancer. Transl Cancer Res. 10:3128–3139. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Gelatti ACZ, Drilon A and Santini FC: Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Lung Cancer. 137:113–122. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Mosca M, Conci N, Di Federico A, Tateo V, Favorito V, Zappi A, Gelsomino F and De Giglio A: First-generation epidermal growth factor receptor inhibitors plus antiangiogenic drugs versus third-generation epidermal growth factor receptor inhibitors in advanced non-small-cell lung cancer: A meta-analysis. JCO Precis Oncol. 7:e23000732023. View Article : Google Scholar : PubMed/NCBI | |
|
Qu F, Zhou Y and Yu W: A review of research progress on mechanisms and overcoming strategies of acquired osimertinib resistance. Anticancer Drugs. 33:e76–e83. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Kurup S, Gesinski D, Assaad K and Reynolds A: Design, synthesis, and evaluation of dual EGFR/AURKB inhibitors as anticancer agents for non-small cell lung cancer. Bioorg Med Chem Lett. 100:1296122024. View Article : Google Scholar : PubMed/NCBI | |
|
Costa DB, Nguyen KSH, Cho BC, Sequist LV, Jackman DM, Riely GJ, Yeap BY, Halmos B, Kim JH, Jänne PA, et al: Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res. 14:7060–7067. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Maione P, Rossi A, Bareschino M, Sacco PC, Schettino C, Casaluce F, Sgambato A and Gridelli C: Irreversible EGFR inhibitors in the treatment of advanced NSCLC. Curr Pharm Des. 20:3894–3900. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Choi YW and Choi JH: Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer? Korean J Intern Med. 32:422–428. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Qu L, Wei X, Gao H, Wang W, Qin H, Tang C, Guo W, Wang H and Liu X: Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 15:299–304. 2012.(In Chinese). PubMed/NCBI | |
|
Vidal ÓJ: Afatinib as first-line therapy in mutation-positive EGFR. Results by type of mutation. Med Clin (Barc). 146 (Suppl 1):S12–S18. 2016.(In Spanish). View Article : Google Scholar | |
|
Won YW, Han JY, Lee GK, Park SY, Lim KY, Yoon KA, Yun T, Kim HT and Lee JS: Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations. J Clin Pathol. 64:947–952. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Yu JY, Yu SF, Wang SH, Bai H, Zhao J, An TT, Duan JC and Wang J: Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21. Chin J Cancer. 35:302016. View Article : Google Scholar : PubMed/NCBI | |
|
Chen LY, Molina-Vila MA, Ruan SY, Su KY, Liao WY, Yu KL, Ho CC, Shih JY, Yu CJ, Yang JC, et al: Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis. Lung Cancer. 94:46–53. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
van Alderwerelt van Rosenburgh IK, Lu DM, Grant MJ, Stayrook SE, Phadke M, Walther Z, Goldberg SB, Politi K, Lemmon MA, Ashtekar KD and Tsutsui Y: Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations. Nat Commun. 13:67912022. View Article : Google Scholar : PubMed/NCBI | |
|
Xu J, Jin B, Chu T, Dong X, Yang H, Zhang Y, Wu D, Lou Y, Zhang X, Wang H and Han B: EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China. Lung Cancer. 96:87–92. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Park S, Lee SY, Kim D, Sim YS, Ryu JS, Choi J, Lee SH, Ryu YJ, Lee JH and Chang JH: Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types. BMC Cancer. 21:522021. View Article : Google Scholar : PubMed/NCBI | |
|
Singh V, Nambirajan A, Malik PS, Thulkar S, Pandey RM, Luthra K, Arava S, Ray R, Mohan A and Jain D: Spectrum of uncommon and compound epidermal growth factor receptor mutations in non-small-cell lung carcinomas with treatment response and outcome analysis: A study from India. Lung Cancer. 149:53–60. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Chiu CH, Yang CT, Shih JY, Huang MS, Su WC, Lai RS, Wang CC, Hsiao SH, Lin YC, Ho CL, et al: Epidermal growth factor receptor tyrosine Kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations. J Thorac Oncol. 10:793–799. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Watanabe M, Oizumi S, Kiuchi S, Yamada N, Yokouchi H, Fukumoto S and Harada M: The effectiveness of afatinib in a patient with advanced lung adenocarcinoma harboring rare G719X and S768I mutations. Intern Med. 57:993–996. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Leventakos K, Kipp BR, Rumilla KM, Winters JL, Yi ES and Mansfield AS: S768I mutation in EGFR in patients with lung cancer. J Thorac Oncol. 11:1798–1801. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu X, Bai Q, Lu Y, Qi P, Ding J, Wang J and Zhou X: Response to tyrosine kinase inhibitors in lung adenocarcinoma with the rare epidermal growth factor receptor mutation S768I: A retrospective analysis and literature review. Target Oncol. 12:81–88. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kutsuzawa N, Takahashi F, Tomomatsu K, Obayashi S, Takeuchi T, Takihara T, Hayama N, Oguma T, Aoki T and Asano K: Successful treatment of a patient with lung adenocarcinoma harboring compound EGFR gene mutations, G719X and S768I, with afatinib. Tokai J Exp Clin Med. 45:113–116. 2020.PubMed/NCBI | |
|
Pham VL, Le TA, Pham CP, Hoa Nguyen TT, Do AT, Nguyen TK, Nguyen MH, Thu Hoang TA, Hao Vuong DT, Tam Nguyen DN, et al: Real-world analysis of afatinib as a first-line treatment for patients with advanced stage non-small-cell lung cancer with uncommon EGFR mutations: A multicenter study in Vietnam. Ther Adv Med Oncol. 16:175883592412429722024. View Article : Google Scholar : PubMed/NCBI | |
|
Hsu PC, Lee SH, Chiu LC, Lee CS, Wu CE, Kuo SC, Ju JS, Huang AC, Li SH, Ko HW, et al: Afatinib in untreated stage IIIB/IV lung adenocarcinoma with major uncommon epidermal growth factor receptor (EGFR) mutations (G719X/L861Q/S768I): A multicenter observational study in Taiwan. Target Oncol. 18:195–207. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Moran T, Taus A, Arriola E, Aguado C, Dómine M, Rueda AG, Calles A, Cedrés S, Viñolas N, Isla D, et al: Clinical activity of afatinib in patients with non-small-cell lung cancer harboring uncommon EGFR mutations: A Spanish retrospective multicenter study. Clin Lung Cancer. 21:428–436.e2. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lee SH, Kim EY, Kim A and Chang YS: Clinical implication and usefulness of de novo EGFR T790M mutation in lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutation. Cancer Biol Ther. 21:741–748. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Barsouk A, Elghawy O, Heidlauf A, Yu C, Wang L, Yang D, Kurian M, Goel K, Rushkin L, Anran Huang A, et al: Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) treated with osimertinib (osi) vs afatinib or erlotinib. Lung Cancer. 195:1079262024. View Article : Google Scholar : PubMed/NCBI | |
|
Nishii T, Yokose T, Miyagi Y, Daigo Y, Ito H, Isaka T, Imai K, Murakami S, Kondo T, Saito H, et al: Clinicopathological features and EGFR gene mutation status in elderly patients with resected non-small-cell lung cancer. BMC Cancer. 14:6102014. View Article : Google Scholar : PubMed/NCBI | |
|
Thomas R, Balaram G, Varayathu H, Ghorpade SN, Kowsik PV, Dharman B, Thomas BE, Ramaswamy V, Nanjaiah T, Patil S, et al: Molecular epidemiology and clinical characteristics of epidermal growth factor receptor mutations in NSCLC: A single-center experience from India. J Cancer Res Ther. 19:1398–1406. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang T, Wan B, Zhao Y, Li C, Liu H, Lv T, Zhan P and Song Y: Treatment of uncommon EGFR mutations in non-small cell lung cancer: New evidence and treatment. Transl Lung Cancer Res. 8:302–316. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wen L, Wang S, Xu W, Xu X, Li M, Zhang Y, Du X and Liu S: Value of serum tumor markers for predicting EGFR mutations in non-small cell lung cancer patients. Ann Diagn Pathol. 49:1516332020. View Article : Google Scholar : PubMed/NCBI | |
|
Kim EY, Kim A, Lee G, Lee H and Chang YS: Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma. BMC Cancer. 18:12212018. View Article : Google Scholar : PubMed/NCBI | |
|
Lai Y, Zhang Z, Li J, Sun D, Zhou Y, Jiang T, Han Y, Huang L, Zhu Y, Li X and Yan X: EGFR mutations in surgically resected fresh specimens from 697 consecutive Chinese patients with non-small cell lung cancer and their relationships with clinical features. Int J Mol Sci. 14:24549–24559. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wang H, Huang J, Yu X, Han S, Yan X, Sun S and Zhu X: Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: A meta-analysis. J Cancer Res Clin Oncol. 140:1901–1909. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Liang H, Li C, Zhao Y, Zhao S, Huang J, Cai X, Cheng B, Xiong S, Li J, Wang W, et al: Concomitant mutations in EGFR 19Del/L858R mutation and their association with response to EGFR-TKIs in NSCLC patients. Cancer Manag Res. 12:8653–8662. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Jiao XD, Qin BD, You P, Cai J and Zang YS: The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base. Lung Cancer. 123:70–75. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Timperi E, Croizer H, Khantakova D, Rana M, Molgora M, Guerriero JL, Mechta-Grigoriou F and Romano E: At the interface of tumor-associated macrophages and fibroblasts: Immune-suppressive networks and emerging exploitable targets. Clin Cancer Res. 30:5242–5251. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Tajaldini M, Saeedi M, Amiriani T, Amiriani AH, Sedighi S, Mohammad Zadeh F, Dehghan M, Jahanshahi M, Zanjan Ghandian M, Khalili P, et al: Cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs); where do they stand in tumorigenesis and how they can change the face of cancer therapy? Eur J Pharmacol. 928:1750872022. View Article : Google Scholar : PubMed/NCBI | |
|
Suzuki J, Tsuboi M and Ishii G: Cancer-associated fibroblasts and the tumor microenvironment in non-small cell lung cancer. Expert Rev Anticancer Ther. 22:169–182. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Garvey CM, Lau R, Sanchez A, Sun RX, Fong EJ, Doche ME, Chen O, Jusuf A, Lenz HJ, Larson B and Mumenthaler SM: Anti-EGFR therapy induces EGF secretion by cancer-associated fibroblasts to confer colorectal cancer chemoresistance. Cancers (Basel). 12:13932020. View Article : Google Scholar : PubMed/NCBI | |
|
Morgillo F, Woo JK, Kim ES, Hong WK and Lee HY: Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res. 66:10100–10111. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Mitsudomi T and Yatabe Y: Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J. 277:301–308. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM, Barón AE, Zeng C and Franklin WA: Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 21:3798–3807. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Madeddu C, Donisi C, Liscia N, Lai E, Scartozzi M and Macciò A: EGFR-mutated non-small cell lung cancer and resistance to immunotherapy: Role of the tumor microenvironment. Int J Mol Sci. 23:64892022. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Y, Zheng X, Ni P, Li D, Dan Q, Wang X, Wang Y, Sun Y, Liu K, Dong Z and Ge H: Targeting the STAT5A/IDO1 axis overcomes radioresistance and reverses the immunosuppressive tumor microenvironment in NSCLC. Int J Oncol. 62:122023. View Article : Google Scholar : PubMed/NCBI | |
|
Lin A, Wei T, Meng H, Luo P and Zhang J: Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. Mol Cancer. 18:1392019. View Article : Google Scholar : PubMed/NCBI | |
|
Burotto M, Ali SA and O'sullivan Coyne G: Class act: Safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma. Expert Opin Drug Saf. 14:97–110. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Liu H, Liu X and Lang L: Gefitinib induces apoptosis in NSCLC cells by promoting glutaminolysis and inhibiting the MEK/ERK signaling pathway. Discov Med. 36:836–841. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao ZQ, Yu ZY, Li J and Ouyang XN: Gefitinib induces lung cancer cell autophagy and apoptosis via blockade of the PI3K/AKT/mTOR pathway. Oncol Lett. 12:63–68. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Li Q, Zhang D, Chen X, He L, Li T, Xu X and Li M: Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer. Sci Rep. 5:160822015. View Article : Google Scholar : PubMed/NCBI | |
|
Han X, Luo R, Wang L, Zhang L, Wang T, Zhao Y, Xiao S, Qiao N, Xu C, Ding L, et al: Potential predictive value of serum targeted metabolites and concurrently mutated genes for EGFR-TKI therapeutic efficacy in lung adenocarcinoma patients with EGFR sensitizing mutations. Am J Cancer Res. 10:4266–4286. 2020.PubMed/NCBI | |
|
Lee SH, Kim EY, Kim T and Chang YS: Compared to plasma, bronchial washing fluid shows higher diagnostic yields for detecting EGFR-TKI sensitizing mutations by ddPCR in lung cancer. Respir Res. 21:1422020. View Article : Google Scholar : PubMed/NCBI | |
|
Masui K, Gini B, Wykosky J, Zanca C, Mischel PS, Furnari FB and Cavenee WK: A tale of two approaches: Complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. Carcinogenesis. 34:725–738. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Hou B, Lu X, Gao DC, Liu QX, Zhou D, Zheng H and Dai JG: REPORT-clinical outcomes of using second-versus first-generation EGFR-tkis for the first-line treatment of advanced NSCLC patients with EGFR mutations: A meta-analysis. Pak J Pharm Sci. 34:1459–1468. 2021.PubMed/NCBI | |
|
Du X, Yang B, An Q, Assaraf YG, Cao X and Xia J: Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors. Innovation (Camb). 2:1001032021.PubMed/NCBI | |
|
Tan CS, Kumarakulasinghe NB, Huang YQ, Ang YLE, Choo JRE, Goh BC and Soo RA: Third generation EGFR TKIs: Current data and future directions. Mol Cancer. 17:292018. View Article : Google Scholar : PubMed/NCBI | |
|
Pirker R: Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol. 28:115–121. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang S and Li J: Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer. Onco Targets Ther. 12:6535–6548. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang S, Tsui ST, Liu C, Song Y and Liu D: EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer. J Hematol Oncol. 9:592016. View Article : Google Scholar : PubMed/NCBI | |
|
Scalvini L, Castelli R, La Monica S, Tiseo M and Alfieri R: Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry. Biochem Pharmacol. 190:1145432021. View Article : Google Scholar : PubMed/NCBI | |
|
Nagano T, Tachihara M and Nishimura Y: Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy. Cells. 7:2122018. View Article : Google Scholar : PubMed/NCBI | |
|
Shi P, Zhang S, Zhu L, Qian G, Ren H, Ramalingam SS, Chen M and Sun SY: The third-generation EGFR inhibitor, osimertinib, promotes c-FLIP degradation, enhancing apoptosis including TRAIL-induced apoptosis in NSCLC cells with activating EGFR mutations. Transl Oncol. 12:705–713. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Venkatesan S, Swanton C, Taylor BS and Costello JF: Treatment-induced mutagenesis and selective pressures sculpt cancer evolution. Cold Spring Harb Perspect Med. 7:a0266172017. View Article : Google Scholar : PubMed/NCBI | |
|
Vander Velde R, Yoon N, Marusyk V, Durmaz A, Dhawan A, Miroshnychenko D, Lozano-Peral D, Desai B, Balynska O, Poleszhuk J, et al: Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures. Nat Commun. 11:23932020. View Article : Google Scholar : PubMed/NCBI | |
|
Li K, Peng ZY, Wang R, Li X, Du N, Liu DP, Zhang J, Zhang YF, Ma L, Sun Y, et al: Enhancement of TKI sensitivity in lung adenocarcinoma through m6A-dependent translational repression of Wnt signaling by circ-FBXW7. Mol Cancer. 22:1032023. View Article : Google Scholar : PubMed/NCBI | |
|
Pang LL, Zhuang WT, Huang YH, Liao J, Li MZ, Lv Y, Zhang L and Fang WF: Uncommon de novo EGFRT790M-Mutant NSCLC characterized with unique genetic features: Clinical response and acquired resistance to the third-generation EGFR-TKIs treatment. Lung Cancer. 190:1075282024. View Article : Google Scholar : PubMed/NCBI | |
|
Denis MG, Vallée A and Théoleyre S: EGFR T790M resistance mutation in non-small-cell lung carcinoma. Clin Chim Acta. 444:81–85. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Shaikh M, Shinde Y, Pawara R, Noolvi M, Surana S, Ahmad I and Patel H: Emerging approaches to overcome acquired drug resistance obstacles to osimertinib in non-small-cell lung cancer. J Med Chem. 65:1008–1046. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Nishino M, Suda K, Kobayashi Y, Ohara S, Fujino T, Koga T, Chiba M, Shimoji M, Tomizawa K, Takemoto T and Mitsudomi T: Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro. Lung Cancer. 126:149–155. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ding K, Peng Z and Xu Y: Triplet therapy overcomes 3rd-EGFR TKI-resistant EGFR-L858R/T790M/C797S in trans and in cis/L718Q mutation. Genes Dis. 12:1014082024. View Article : Google Scholar : PubMed/NCBI | |
|
Lim SM, Schalm SS, Lee EJ, Park S, Conti C, Millet YA, Woessner R, Zhang Z, Tavera-Mendoza LE, Stevison F, et al: BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer. Ther Adv Med Oncol. 16:175883592412806892024. View Article : Google Scholar : PubMed/NCBI | |
|
Ahmadi A, Mohammadnejadi E and Razzaghi-Asl N: Gefitinib derivatives and drug-resistance: A perspective from molecular dynamics simulations. Comput Biol Med. 163:1072042023. View Article : Google Scholar : PubMed/NCBI | |
|
Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, Lifshits E, Brown A, Lee C, Christensen JG, et al: Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene. 29:2346–2356. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kubo T, Yamamoto H, Lockwood WW, Valencia I, Soh J, Peyton M, Jida M, Otani H, Fujii T, Ouchida M, et al: MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer. 124:1778–1784. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Nukaga S, Yasuda H, Tsuchihara K, Hamamoto J, Masuzawa K, Kawada I, Naoki K, Matsumoto S, Mimaki S, Ikemura S, et al: Amplification of EGFR wild-type alleles in non-small cell lung cancer cells confers acquired resistance to mutation-selective EGFR tyrosine kinase inhibitors. Cancer Res. 77:2078–2089. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Presutti D, Santini S, Cardinali B, Papoff G, Lalli C, Samperna S, Fustaino V, Giannini G and Ruberti G: MET gene amplification and MET receptor activation are not sufficient to predict efficacy of combined MET and EGFR inhibitors in EGFR TKI-resistant NSCLC cells. PLoS One. 10:e01433332015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Xu Y, Xu J, Zhong H, Xia J and Zhong R: Osimertinib for EGFR-mutant NSCLC patients with acquired T790M and EGFR amplification after first-generation EGFR-TKI resistance. Cancer Sci. 116:753–763. 2025. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Z, Yang S and Wang Q: Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer. Biomark Res. 7:272019. View Article : Google Scholar : PubMed/NCBI | |
|
Nie N, Li J, Zhang J, Dai J, Liu Z, Ding Z, Wang Y, Zhu M, Hu C, Han R, et al: First-line osimertinib in patients with EGFR-mutated non-small cell lung cancer: Effectiveness, resistance mechanisms, and prognosis of different subsequent treatments. Clin Med Insights Oncol. 16:117955492211347352022. View Article : Google Scholar : PubMed/NCBI | |
|
Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, et al: Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 17:77–88. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, Ohashi K, Janjigian YY, Spitzler PJ, Melnick MA, et al: HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFR T790M mutation. Cancer Discov. 2:922–933. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ding D, Zhang J, Luo Z, Wu H, Lin Z, Liang W and Xue X: Analysis of the lncRNA-miRNA-mRNA network reveals a potential regulatory mechanism of EGFR-TKI resistance in NSCLC. Front Genet. 13:8513912022. View Article : Google Scholar : PubMed/NCBI | |
|
Liu S, Li S, Hai J, Wang X, Chen T, Quinn MM, Gao P, Zhang Y, Ji H, Cross DAE and Wong KK: Targeting HER2 aberrations in non-small cell lung cancer with osimertinib. Clin Cancer Res. 24:2594–2604. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Jonsdottir G, Smith M, Wood S, Hejleh TA and Furqan M: Activity of osimertinib in a patient with stage IV non-small cell lung cancer harboring HER2 exon 19, p.L755P mutation: Case report. Transl Lung Cancer Res. 12:927–932. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Rastogi I, Rajanna S, Webb A, Chhabra G, Foster B, Webb B and Puri N: Mechanism of c-Met and EGFR tyrosine kinase inhibitor resistance through epithelial mesenchymal transition in non-small cell lung cancer. Biochem Biophys Res Commun. 477:937–944. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Soucheray M, Capelletti M, Pulido I, Kuang Y, Paweletz CP, Becker JH, Kikuchi E, Xu C, Patel TB, Al-Shahrour F, et al: Intratumoral heterogeneity in EGFR-mutant NSCLC results in divergent resistance mechanisms in response to EGFR tyrosine kinase inhibition. Cancer Res. 75:4372–4383. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lu Y, Liu Y, Oeck S, Zhang GJ, Schramm A and Glazer PM: Hypoxia induces resistance to EGFR inhibitors in lung cancer cells via upregulation of FGFR1 and the MAPK pathway. Cancer Res. 80:4655–4667. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Comaills V, Kabeche L, Morris R, Buisson R, Yu M, Madden MW, LiCausi JA, Boukhali M, Tajima K, Pan S, et al: Genomic instability is induced by persistent proliferation of cells undergoing epithelial-to-mesenchymal transition. Cell Rep. 17:2632–2647. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Yochum ZA, Cades J, Wang H, Chatterjee S, Simons BW, O'Brien JP, Khetarpal SK, Lemtiri-Chlieh G, Myers KV, Huang EH, et al: Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. Oncogene. 38:656–670. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chen K, Xu J, Tong YL, Yan JF, Pan Y, Wang WJ, Zheng L, Zheng XX, Hu C, Hu X, et al: Rab31 promotes metastasis and cisplatin resistance in stomach adenocarcinoma through Twist1-mediated EMT. Cell Death Dis. 14:1152023. View Article : Google Scholar : PubMed/NCBI | |
|
Burns TF, Dobromilskaya I, Murphy SC, Gajula RP, Thiyagarajan S, Chatley SN, Aziz K, Cho YJ, Tran PT and Rudin CM: Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancer. Mol Cancer Res. 11:329–338. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Fukuda K, Takeuchi S, Arai S, Kita K, Tanimoto A, Nishiyama A and Yano S: Glycogen synthase kinase-3 inhibition overcomes epithelial-mesenchymal transition-associated resistance to osimertinib in EGFR-mutant lung cancer. Cancer Sci. 111:2374–2384. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Raoof S, Mulford IJ, Frisco-Cabanos H, Nangia V, Timonina D, Labrot E, Hafeez N, Bilton SJ, Drier Y, Ji F, et al: Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer. Oncogene. 38:6399–6413. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wu Q, Zhen Y, Shi L, Vu P, Greninger P, Adil R, Merritt J, Egan R, Wu MJ, Yin X, et al: EGFR inhibition potentiates FGFR inhibitor therapy and overcomes resistance in FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov. 12:1378–1395. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Hu S, Fu W, Li T, Yuan Q, Wang F, Lv G, Lv Y, Fan X, Shen Y, Lin F, et al: Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency. Sci Transl Med. 9:eaag03392017. View Article : Google Scholar : PubMed/NCBI | |
|
Lin Z, Wang Q, Jiang T, Wang W and Zhao JJ: Targeting tumor-associated macrophages with STING agonism improves the antitumor efficacy of osimertinib in a mouse model of EGFR-mutant lung cancer. Front Immunol. 14:10772032023. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Zhang T, Guo L, Ren T and Yang Y: Stromal extracellular matrix is a microenvironmental cue promoting resistance to EGFR tyrosine kinase inhibitors in lung cancer cells. Int J Biochem Cell Biol. 106:96–106. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Peng S, Wang R, Zhang X, Ma Y, Zhong L, Li K, Nishiyama A, Arai S, Yano S and Wang W: EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression. Mol Cancer. 18:1652019. View Article : Google Scholar : PubMed/NCBI | |
|
Hsu KH, Huang YH, Tseng JS, Chen KC, Ku WH, Su KY, Chen JJW, Chen HW, Yu SL, Yang TY and Chang GC: High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients. Lung Cancer. 127:37–43. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang W, Wang J, Liang J, He Z, Wang K and Lin H: RNA methylation of CD47 mediates tumor immunosuppression in EGFR-TKI resistant NSCLC. Br J Cancer. 132:569–579. 2025. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Q, Xia L, Wang J, Zhu S, Wang J, Li X, Yu Y, Li Z, Wang Y, Zhu G and Lu S: EGFR-mutant NSCLC may remodel TME from non-inflamed to inflamed through acquiring resistance to EGFR-TKI treatment. Lung Cancer. 192:1078152024. View Article : Google Scholar : PubMed/NCBI | |
|
Yao X, Gao C, Sun C, Chen ZS and Zhuang J: Epigenetic code underlying EGFR-TKI resistance in non-small cell lung cancer: Elucidation of mechanisms and perspectives on therapeutic strategies. Drug Discov Today. 30:1043212025. View Article : Google Scholar : PubMed/NCBI | |
|
Quan C, Chen Y, Wang X, Yang D, Wang Q, Huang Y, Petersen RB, Liu X, Zheng L, Li Y and Huang K: Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Cancer Lett. 495:41–52. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Bui VNV, Daugaard TF, Sorensen BS and Nielsen AL: Expression of the non-coding RNA nc886 facilitates the development of tyrosine kinase inhibitor resistance in EGFR-mutated non-small-cell lung cancer cells. Biochem Biophys Res Commun. 731:1503952024. View Article : Google Scholar : PubMed/NCBI | |
|
Hong W, Wu Q, Zhang J and Zhou Y: Prognostic value of EGFR 19-del and 21-L858R mutations in patients with non-small cell lung cancer. Oncol Lett. 18:3887–3895. 2019.PubMed/NCBI | |
|
Soleimani-Meigooni DN and Rabinovici GD: Tau PET visual reads: Research and clinical applications and future directions. J Nucl Med. 64:822–824. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
George RS, Htoo A, Cheng M, Masterson TM, Huang K, Adra N, Kaimakliotis HZ, Akgul M and Cheng L: Artificial intelligence in prostate cancer: Definitions, current research, and future directions. Urol Oncol. 40:262–270. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Luo Q, Zhang L, Luo C and Jiang M: Emerging strategies in cancer therapy combining chemotherapy with immunotherapy. Cancer Lett. 454:191–203. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Rahmat K, Mumin NA, Hamid MTR, Hamid SA and Ng WL: MRI breast: Current imaging trends, clinical applications, and future research directions. Curr Med Imaging. 18:1347–1361. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Bajbouj K, Al-Ali A, Ramakrishnan RK, Saber-Ayad M and Hamid Q: Histone modification in NSCLC: Molecular mechanisms and therapeutic targets. Int J Mol Sci. 22:117012021. View Article : Google Scholar : PubMed/NCBI | |
|
Reungwetwattana T, Weroha SJ and Molina JR: Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 13:252–266. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Chia PL, Dobrovic A, Dobrovic A and John T: Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin Epidemiol. 6:423–432. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Hsu J, Annunziata JF, Burns E, Bernicker EH, Olsen RJ and Thomas JS: Molecular signatures of KRAS-mutated lung adenocarcinoma: Analysis of concomitant EGFR, ALK, STK11, and PD-L1 status. Clin Pathol. 15:2632010X2211020542022. View Article : Google Scholar : PubMed/NCBI | |
|
Gkolfinopoulos S and Mountzios G: Beyond EGFR and ALK: Targeting rare mutations in advanced non-small cell lung cancer. Ann Transl Med. 6:1422018. View Article : Google Scholar : PubMed/NCBI | |
|
Hirsch FR, Suda K, Wiens J and Bunn PA Jr: New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet. 388:1012–1024. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Weishan H, Donglin Z, Guangmei D, Wenya L, Fasheng W and Jibing C: Immunoradiotherapy for NSCLC: Mechanisms, clinical outcomes, and future directions. Clin Transl Oncol. 26:1063–1076. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Selzer E: Impact of molecular targets in cancer drug development: Historical influence and future perspectives. Expert Rev Clin Pharmacol. 3:161–163. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Amaravadi RK, Kimmelman AC and Debnath J: Targeting autophagy in cancer: Recent advances and future directions. Cancer Discov. 9:1167–1181. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Black A and Morris D: Personalized medicine in metastatic non-small-cell lung cancer: Promising targets and current clinical trials. Curr Oncol. 19 (Suppl 1):S73–S85. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Saxena A, Becker D, Preeshagul I, Lee K, Katz E and Levy B: Therapeutic effects of repurposed therapies in non-small cell lung cancer: What is old is new again. Oncologist. 20:934–945. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Harmey D, Griffin PR and Kenny PJ: Development of novel pharmacotherapeutics for tobacco dependence: Progress and future directions. Nicotine Tob Res. 14:1300–1318. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ciardiello D, Elez E, Tabernero J and Seoane J: Clinical development of therapies targeting TGFβ: Current knowledge and future perspectives. Ann Oncol. 31:1336–1349. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kannan K and Mohan S: Targeting exon mutations in NSCLC: Clinical insights into LAG-3, TIM-3 pathways, and advances in fourth-generation EGFR-TKIs. Med Oncol. 42:1962025. View Article : Google Scholar : PubMed/NCBI |
